Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD68-ET3-LV Gene Therapy for Severe Hemophilia A
NCT05265767Phase 1Completed
- Sponsor
- Christian Medical College, Vellore
- Start
- Apr 2022
- Primary completion
- Jun 2024
- Modality
- Gene Editing, Gene Silencing, Lentiviral Vectors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ET3 in hemophilia A, sponsored by Christian Medical College, Vellore. Primary endpoints: Number of study participants experiencing serious adverse events at 12 weeks, Severity of serious adverse events at 12 weeks and 1 more. Started Apr 2022; status: completed.
02
Drugs
ET3
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT05265767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05265767.